Bristol Myers Squibb Company
NEWS
The trial was assessing if multiple myeloma drug Empliciti could move forward as a front-line treatment for the disease.
Although March looks to be a busy month for the U.S. Food and Drug Administration, several of the PDUFA dates for this week were for drugs under Priority Review.
The most recent BioSpace Ideal Employer Report revealed the impact of team dynamics on employees within life sciences organizations.
Mid-February had a solid number of clinical trial announcements. Here’s a look.
The Phase II trial did not meet its primary endpoint.
Long-term data boosts the efficacy of Bristol-Myers Squibb’s checkpoint inhibitor, Opdivo, as a treatment for renal cell carcinoma.
It was a busy week for biotech quarterly and annual reports. Here’s a look at some of the top stories including Bristol-Myers Squibb, AbbVie, GSK, Merck and more.
“Anteros Pharmaceuticals is the first of several companies that BioMotiv and Bristol-Myers Squibb intend to form under the Strategic Partnership Agreement,” said Satish Jindal, BioMotiv’s chief executive officer.
The biotech Hotbed known as Pharm Country, which includes New Jersey, Connecticut, New York Pennsylvania and Rhode Island, is an area of rapid growth and change.
JOBS
IN THE PRESS